SCHEMBL3324219

SCHEMBL3324219

COc1cc2c(cc1OC)CN(Cc1cccc(O)c1O)CC2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.63
MAPT P10636 2/20 0.63
RAB9A P51151 2/20 0.63
GAA P10253 1/20 0.63
TDP1 Q9NUW8 1/20 0.62
ABCB1 P08183 7/20 0.61
TSHR P16473 2/20 0.58
ABCC1 P33527 1/20 0.58
ABCG2 Q9UNQ0 1/20 0.58
POLB P06746 1/20 0.56
ALDH1A1 P00352 1/20 0.56
ALOX15 P16050 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
HSD17B10 Q99714 1/20 0.56
DRD3 P35462 3/20 0.56
DRD2 P14416 2/20 0.56
DRD4 P21917 2/20 0.56
TMEM97 Q5BJF2 2/20 0.56
KMT2A Q03164 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3320804 0.99 KDM4E (0.62) KDM4EMAPTRAB9AGAATDP1
SCHEMBL3321015 0.87 DRD3 (0.54) KDM4EMAPTRAB9AGAATDP1
SCHEMBL3046470 0.86 DRD2 (0.69) KDM4ETDP1DRD3DRD2DRD4
Hydrochloric Acid SCHEMBL3318492 0.85 DRD3 (0.53) KDM4EMAPTRAB9AGAATDP1
SCHEMBL3049243 0.82 DRD3 (0.70) KDM4ETDP1ABCB1DRD3DRD2
SCHEMBL3322960 0.82 KDM4E (0.71) KDM4EMAPTRAB9AGAATDP1
SCHEMBL3049241 0.82 DRD3 (0.71) KDM4EMAPTTDP1TSHRDRD3
Hydrochloric Acid SCHEMBL3320118 0.81 KDM4E (0.70) KDM4EMAPTRAB9AGAATDP1
SCHEMBL3057840 0.81 KDM4E (0.55) KDM4EMAPTRAB9AGAATDP1
SCHEMBL3058965 0.80 CA2 (0.67) KDM4EMAPTRAB9AGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185521-A2 COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES Exonhit Therapeutics SA (FR) 2010-05-19 EP disclosed
US-20100120810-A1 COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES EXONHIT THERAPEUTICS SA (FR) 2010-05-13 US disclosed
US-20100120810-A1 COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES EXONHIT THERAPEUTICS SA (FR) 2010-05-13 US disclosed
US-20100120810-A1 COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES EXONHIT THERAPEUTICS SA (FR) 2010-05-13 US disclosed
WO-2009007457-A2 COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES EXONHIT THERAPEUTICS SA (FR) 2009-01-15 WO disclosed
WO-2009007457-A2 COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES EXONHIT THERAPEUTICS SA (FR) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120810-A1 COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES RAC1, RAC2, RAC3 KDM4E 3958/4885MAPT 2679/4885RAB9A 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.